Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11635625 | 0.84 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL27810411 | 0.84 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL29372886 | 0.83 | ADRB2 (0.50) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL20995244 | 0.83 | ADRB2 (0.50) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL16958712 | 0.83 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL18854471 | 0.83 | ADRB2 (0.50) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL14967003 | 0.83 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL21066869 | 0.82 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL2522805 | 0.82 | TRPV4 (0.50) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL1506620 | 0.82 | S1PR1 (0.46) | LMNAPOLBS1PR1TRPA1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114436955-B | Tetrahydroquinoline and benzomorpholine derivatives or salts thereof, and preparation method and application thereof | 复旦大学 | 2024-08-09 | — | — | CN | disclosed |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11771680-B2 | Pyrrole compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2023153169-A1 | ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT | キヤノン株式会社 | 2023-08-17 | — | — | WO | disclosed |
| CN-114436955-A | Tetrahydroquinoline and benzomorpholine derivatives or salts thereof, and preparation method and application thereof | 复旦大学 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021127397-A1 | NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020219904-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219906-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-29 | — | — | WO | disclosed |
| US-20180127415-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-9890161-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| US-7807670-B2 | Inhibitors of papilloma virus | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2010-10-05 | — | — | US | disclosed |
| US-7807670-B2 | Inhibitors of papilloma virus | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2010-10-05 | — | — | US | disclosed |
| US-20100041649-A1 | INHIBITORS OF PAPILLOMA VIRUS | YOAKIM CHRISTIANE | 2010-02-18 | — | — | US | disclosed |
| US-20100041649-A1 | INHIBITORS OF PAPILLOMA VIRUS | YOAKIM CHRISTIANE | 2010-02-18 | — | — | US | disclosed |
| US-20100004295-A1 | Hydrazine amide derivative | SHIONOGI & CO., LTD. | 2010-01-07 | — | — | US | disclosed |
| US-7589089-B2 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7528167-B2 | Inhibitors of papilloma virus | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-05-05 | — | — | US | disclosed |
| US-20080058331-A1 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. | 2008-03-06 | — | — | US | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | SLC6A2 3580/4885SLC6A4 4201/4885SLC6A3 3298/4885 |
| US-20080058331-A1 | Inhibitors for GlyT-1 | GLRA1, SLC1A2, AGXT | SLC6A2 63/4885SLC6A4 36/4885SLC6A3 71/4885 |
| US-11771680-B2 | Pyrrole compounds | PKD1, ADCYAP1R1, PYCR1 | SLC6A2 3723/4885SLC6A4 3369/4885SLC6A3 2520/4885 |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | SLC6A2 1659/4885SLC6A4 1952/4885SLC6A3 2245/4885 |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | DHPS, FDPS, DPYD | SLC6A2 3131/4885SLC6A4 2616/4885SLC6A3 2265/4885 |
| US-20100004295-A1 | Hydrazine amide derivative | NPY5R, NPY1R, NPY2R | SLC6A2 824/4885SLC6A4 726/4885SLC6A3 707/4885 |
| US-20180127415-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | SLC6A2 3744/4885SLC6A4 4189/4885SLC6A3 3844/4885 |
| US-20100041649-A1 | INHIBITORS OF PAPILLOMA VIRUS | REV1, CDKN1A, RB1 | SLC6A2 4847/4885SLC6A4 4696/4885SLC6A3 3910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.